Biotechnology - Mergers & Acquisitions, Cardio-vascular

Filter

Popular Filters

uniQure acquires cardiology gene therapy firm InoCard

12-08-2014

Netherlands-based human gene therapy firm uniQure says it has acquired Germany’s InoCard GmbH, an innovative,…

BiotechnologyCardio-vascularGermanyInoCardMergers & AcquisitionsNetherlandsuniQure

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million

05-11-2013

San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

Serodus to acquire Phlogo to expand cardiovascular portfolio

12-07-2013

Norwegian biopharma company Serodus (Oslo Axess: SER) says that, following approval by an extraordinary…

BiotechnologyCardio-vascularMergers & AcquisitionsPhlogoSER130SER140Serodus

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

Shin Poong and LFB set up joint venture to manufacture biotech products

11-01-2013

South Korean drugmaker Shin Poong Pharmaceutical (KOSPI: 019170) and France's Laboratoire francais du…

Asia-PacificAtrynBiotechnologyCardio-vascularFVIIaLaboratoire francais du Fractionnement et desMergers & AcquisitionsProductionShin Poong Pharmaceutical

US FDA clears Amarin's Vascepa, a competitor for Lovaza

30-07-2012

The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

J&J's Janssen files Xarelto with FDA for new indication; buys Chinese firm

03-05-2012

US health care major Johnson & Johnson's (NYSE: JNJ) subsidiary Janssen Research & Development says it…

Asia-PacificBayerBioseal BiotechBiotechnologyCardio-vascularJanssenJohnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationXarelto

Back to top